Information For Authors
- Manuscript Submission Guidelines
- Author Benefits Program
- Open Access Policy
- NIH/HHMI Wellcome Trust Policies
- Self-Archiving Policy
Submitting Your Manuscript
Human Gene Therapy welcomes format-neutral manuscripts for first-time submissions. Newly submitted manuscripts will not be un-submitted for formatting issues. However, after the initial peer review process, revised submissions must follow correct journal formatting and file guidelines, as described below in the Instructions for Authors. Please note that there are certain compulsory elements (i.e.: IRB approvals, author disclosures, etc.) that must be included in all new submissions. Manuscripts submitted without this information will be un-submitted and the submitting author will be asked to add the required components.
The submitting author is required to complete the submission using an ORCID identifier. Please visit the ORCID website for more information, or to register. You must have an account in ScholarOne for Human Gene Therapy before logging in with an ORCID identifier.
Manuscript Submission Site
Create an Account in ScholarOne
If you do not already have an account in ScholarOne for Human Gene Therapy, you will need to create one. Once you create your account, you may log in to the system to begin your submission. Each listed author on a submission must either have an account, or have one created, in the submission system.
See JOURNAL STANDARDS AND BEST PRACTICES STATEMENT
Check the Journal’s PEER REVIEW POLICIES
Please read all the instructions to authors before submitting your article. For more information and all inquiries on manuscript submission, please contact the HGT Editorial Office.
A cover letter is required with your submission. Summarize the major findings of the manuscript in the context of adding value to the field of gene therapy. Confirm that the material has not been published or submitted for publication elsewhere. State the co-authors’ approval and provide a statement on non-duplicate submission. Include any other information of interest such as special submissions or pre-submission inquiries.
All authors, including the co-authors, should be responsible for a significant part of the manuscript. All authors and co-authors should have taken part in writing the manuscript, reviewing it, and revising its intellectual and technical content. Any author whose name appears on a manuscript assumes responsibility and accountability for the results.
All Original submissions must contain:
- An Institutional Review Board (IRB) approval (or waiver) statement in the Methods section
- Acknowledgments section (if applicable) after the Conclusion of the manuscript, followed by
- An Author Contribution statement for each listed author, followed by
- An Author Disclosure Statement for each author listed on a submission, even if there are no conflicts to disclose, followed by,
- Funding statement(s), even if there is no funding information to declare.
Human Subjects: Patient Consent/Release
If applicable, it is incumbent upon the author(s) to obtain patient release statements of permission to reproduce any identifiable images of patients. The Journal does not provide a generic patient release form. Any identifying information should not be published in descriptions or photographs unless the information is essential for scientific purposes and the patient (or parent/guardian) gives written informed consent for publication. Informed consent for this purpose requires that an identifiable patient be shown the manuscript to be submitted. Authors should disclose to these patients whether any potential identifiable material might be available via the Internet as well as in print after publication. Nonessential identifying details should be omitted. Informed consent should be obtained if there is any doubt that anonymity can be maintained. For example, masking the eye region in photographs of patients is inadequate protection of anonymity. If identifying characteristics are de-identified, the manuscript should contain assurances/statements that such changes do not distort scientific meaning.
In keeping with patients' rights of privacy, the Journal does not require the submission of patient consent forms, but instead requires the author(s) to retain and archive all patient consent documentation. Upon submission of a manuscript for review, the authors must make a statement in a cover letter to the Editor/Journal which attests that they have received and archived written patient consent.
All manuscripts must be prepared in accordance with the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals (ICMJE Recommendations).
When submitting your manuscript for peer review, be prepared to:
- Enter the full title of the manuscript
- Enter the full names and institutional affiliations of ALL listed authors
- Enter ALL listed authors' institutional email addresses
- Identify the corresponding author
- Enter a running (abbreviated) title of no more than 50 characters (including spaces).
- Enter 3–6 keywords or phrases.
- For research articles, reviews, and clinical protocols, provide an unstructured abstract of no more than 300 words. Methods protocol submissions should limit the abstract to 100 words.
- Provide the names and email addresses of at least five potential preferred reviewers familiar with the field. Please make sure preferred reviewers are not from your university or institution or with whom you have collaborated. Anyone whom the author does not want to be considered should also be named as a non-preferred reviewer. Ultimate reviewer selection is at the Editor’s discretion.
Create an Effective Title
- Manuscript titles should be brief, contain key terms, and clearly identify the purpose of the work
- Manuscript titles should not exceed 15 -18 words. Exceptions can be made with the Editor’s approval
- Manuscript titles should be direct and to the point. Remember that the journal has a global readership, so clear and concise non-vernacular language is most effective
- Avoid the use of specific locations in the title
- Do not use proprietary/trademarked names in the title
- Do not use acronyms in the title unless they are universally recognized and accepted
- NOTE: The title page of your submission must be included as part of your main text document (not as a separate file).
All file names should be in English and contain only alphanumeric characters. Do not include spaces, symbols, special characters, dashes, dots, or underscores. Label each file with the type of content contained in the file (i.e.: Text; Tables; FigureLegends; Fig1, etc.). It is not necessary to name your files with the title of the submission.
Important: Please upload individual files of all manuscript material as described herein — please do NOT upload a combined PDF file containing all material in your submission.
Preparation of Manuscript
Prepare text of manuscripts, figure legends, and tables in Microsoft Word, double spaced. The order of elements in each manuscript should be:
- Main text file headers (each header starts on a new page)
- Title page (with full manuscript title, all contributing authors and their affiliations, a short running title, a denotation of the corresponding author, and a list of 3-6 keywords
- Abstract (the word limit differs for each submission type; see Article Types and Word Limits)
- Main text (do not embed figures or tables in text file)
- Conclusion (as a separate paragraph, not as part of the Discussion section)
- Acknowledgments (if applicable)
- Authorship confirmation statement
- Author(s’) disclosure statement(s)
- Funding statement
- Figure legends
- Supplemental files (if applicable. If the submission is accepted, Supplemental Information will NOT be published in the Just Accepted/LION platform, but instead will be published in the Online Now (epub) and final versions of the article. Supplemental Information will not be copyedited or typeset; it will be posted online as supplied.)
References must be prepared in Word, double spaced, and numbered consecutively as they are cited in the text (using superscript numbers). Include the reference section as part of the main text file, not as a separate file. References appearing for the first time in tables and figures must be numbered in sequence with those cited in the text where the table or figure is mentioned. Use journal abbreviations as provided by PubMed/Medline. Author names should start with a capital letter, but must not be in all caps. If more than three authors are listed on an article, list the first three authors and use et al. (not italic) after the third author’s name. Include the year of publication, volume number, and inclusive page range.
If references to personal communications or unpublished data are used, they are not to be in the list of references. They should be referred to in the text in parentheses: (e.g., Jones AB, personal communication, year). Include among the references any articles that have been accepted but have not yet published; identify the name of the publication and add "In Press." If the reference has been published online, provide the DOI number in place of the page range. If a work has been submitted but is still under peer review, supply the authors’ names and list the manuscript title, followed by “Submitted; under review, year of submission.” (e.g., Jones and Smith, manuscript title, submitted; under review, 2018). Do NOT include the citation in the reference list.
Note: “Submitted” and “in press” citations should be updated at the page proofs stage whenever possible.
Sample style for references:
Berns KI. The unusual properties of the AAV inverted terminal repeat. Hum Gene Ther 2020;3):518-523.
Journal article (with more than three authors):
Rubin JD, Nguyen TV, Allen KL, et al. Comparison of gene delivery to the kidney by adenovirus, adeno-associated virus, and lentiviral vectors after intravenous and direct kidney injections. Hum Gene Ther 2019;30:1559-1571.
Herzog RW, Zolotukhin S, eds. A Guide to Human Gene Therapy. Singapore: World Scientific Publishing Co. Pte. Ltd., 2010.
Figure legends should be uploaded as a separate Word file and double spaced. In the legend, provide explanations for any abbreviations, arrows, etc. that appear in the figure. If the illustration is taken from a copyrighted publication, permission must be secured, appropriate credit must be given in the legend, and a corresponding reference must appear in the reference section. All permissions must be supplied at the time of submission.
All tables should be prepared in one single Word file. Provide a title for each table. Cite tables in sequence in the text. Explain abbreviations used in the body of the table in footnotes. All other types of table footnotes should be designated using superscript letters, not symbols. If the table is taken from a copyrighted publication, permission must be secured, appropriate credit must be given in the legend, and a corresponding reference must appear in the reference section. All permissions must be supplied at the time of submission.
- Submission of high resolution .TIFF or .EPS figure files is strongly recommended.
- Figures should not be embedded within the manuscript file.
- Cite figures consecutively in text within parentheses.
- A legend should be supplied for each figure and all legends numbered consecutively.
- Images should not show the name of a patient or a manufacturer.
- Do not include any illustrations as part of your text file.
- The Journal will publish color photographs, but the author will be charged for the cost of color printing.
We encourage authors of manuscripts accepted by Human Gene Therapy to submit interesting images for consideration of publication on the Journal cover. This includes images that were not published within the manuscript, but are related to the content. Please ensure that they are not submitted or published elsewhere. Send images or questions to the HGT Editorial Office.
Following the references, provide the name and complete affiliation and institutional email address of the person to whom correspondence should be sent.
To upload a revision of a manuscript, the submitting author should log in to their Author Center and click on “Revised Manuscripts in Draft.” All revised submissions will be required to meet all formatting conditions described herein. Submissions that do not satisfy these requirements will be un-submitted and returned to the submitting author for proper configuration.
Journal Policies on:
Licensing Information: OPEN ACCESS and Copyright
Data Sharing and Preprint Policies
Post-Acceptance and Post-Publication Policies
Correction Statements / Retractions
Reprints, Permissions, & Social Media Use
Plagiarism Detection Software
Definitions of Scientific Misconduct
Responding to Allegations of Scientific Misconduct
Press Embargo Policy
Archiving and Preservation
For questions regarding manuscript submissions, contact our Author Services Division.
Ensure maximum visibility, discoverability, and impact for your article with our Liebert Open Access (OA) option
Does your research funder have an open access mandate or would you like to expand the dissemination of your research?
The Liebert Open Access option enables authors to publish open access in our esteemed subscription-based journals.
The benefits of Liebert Open Access include:
- High visibility; open access articles are freely available online upon publication
- You retain copyright with the open access license allowing broad dissemination of your research
- You can freely share your article in repositories and research networks without restrictions
- Easy compliance with open access mandates
- Rigorous editorial and peer-review
- Targeted email announcement featuring a direct link to article
Identification and Marketing
Open access articles are listed with an OA icon in journal tables of content (TOC), TOC alerts, and in marketing announcements. Open access articles are highlighted and promoted in targeted email announcements to thousands of research leaders in your field.
Copyright and Licensing
If you choose to publish with open access, you will retain copyright of your article and a Creative Commons license will be applied. The liberal Creative Commons Attribution 4.0 (CC-BY) license is the default open access license used at Mary Ann Liebert, Inc., publishers. The CC-BY license permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.
Ordering Open Access
Once your article has been accepted for publication in a journal, you will receive an email with information on ordering Liebert Open Access. If you would like more information about Liebert Open Access or would like to order open access, please email firstname.lastname@example.org.
Publishing open access includes an article publication charge (APC) and authors are asked to fill out a short open access order form. You can pay by credit card or receive an invoice to be returned with payment or via bank transfer. Please remember that traditional subscription journals can carry mandatory or optional author fees. The Liebert Open Access APC does not cover or replace existing publication or author fees.
Publishing biomedical or biotechnology research?
Biomedical researchers should consider publishing in BioResearch Open Access, a fully open access peer-reviewed journal dedicated to publishing top research in the biomedical and biotechnology fields. For details, please visit the information for authors on the journal website.
*Please note that PubMedCentral, not the Publisher, has sole control over when the paper is made live on PMC.
Browse journals in the Liebert Open Access portfolio:
NIH Public Access Policy: In order to assist our authors who have NIH funding to comply with this policy, Mary Ann Liebert, Inc. publishers will deposit the final accepted paper (after copy-editing and proofreading) to PubMed Central (PMC) on behalf of the authors. Authors need not take any action. The manuscript's public access posting on PMC will occur 12 months after final publication. This service is provided free of charge. Please note that authors may not deposit manuscripts directly to PMC or other sites without permission from Mary Ann Liebert, Inc.
Publishing in Subscription Journals
By signing the copyright transfer statement, authors still retain a set of rights that allow for self-archiving.
Authors may archive their preprint manuscripts (version prior to peer review) at any time without restrictions. Authors may archive their postprint manuscripts (accepted version after peer review) in institutional repositories, preprint servers, and research networks after a 12 month embargo. The 12 month embargo period begins when the article is published online. Postprints must not be used for commercial purposes and acknowledgement must be given to the final publication, and publisher, by inserting the DOI number of the article in the following sentence: “Final publication is available from Mary Ann Liebert, Inc., publishers http://dx.doi.org/[insert DOI]”. Authors may archive on their personal website without an embargo provided their manuscript is updated with an acknowledgement to the publisher copyright and final published version.
The final published article (version of record) can never be archived in a repository, preprint server, or research network.
Publishing Open Access
Authors that wish to easily comply with funder or institutional open access mandates should consider publishing open access. Liebert Open Access option allows authors to make their research freely available online without restrictions. Additionally, Liebert Open Access option allows authors to retain copyright, archive and share the final published version of their article without restrictions. To publish open access please email email@example.com or visit Liebert Open Access for more information.